MIRA PHARMACEUTICALS, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) on May 21, 2025, covering events occurring on May 15 and May 16, 2025. The filing addresses significant changes in executive leadership, specifically the departure of the Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and the terms of a new employment agreement.
Material Changes
- Resignation of Principal Officer: Michelle Yanez resigned as Chief Financial Officer, Treasurer, and Secretary effective May 16, 2025. The separation was mutual and not based on any disagreement with the Company.
- Appointment of Principal Officer: Alan Weichselbaum was appointed as Chief Financial Officer effective May 15, 2025, with an employment start date of May 19, 2025.
- Compensation Arrangement: Mr. Weichselbaum's employment agreement includes an annual salary of $60,000 and an option grant of up to 75,000 shares of Common Stock. The options vest in two tranches: 37,500 shares after six months and 37,500 shares after twelve months, contingent on continued employment.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, market outlook, or specific risk factors. Management commentary is limited to the background of the new CFO, highlighting his 30+ years of experience in corporate finance, capital markets, and strategic advisory, including roles at Telomir Pharmaceuticals, FinWise Bancorp, and The Wexus Group. The employment agreement is on an at-will basis, allowing termination by either party at any time.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price of the 75,000 stock options granted to Alan Weichselbaum by reviewing Exhibit 10.1 (Employment Agreement).
- Confirm the transition timeline for financial reporting responsibilities between the outgoing and incoming CFO.
- Review the Company's recent 10-K or 10-Q filings for the most current financial position, as this 8-K contains no financial metrics.
- Monitor future filings for any additional executive departures or changes in capital structure related to the new CFO's strategic initiatives.